Read enzyme data with controlled experiments. Explore energy barriers, saturation and inhibitor binding, then connect catalytic capacity to cellular energy.
A lower reaction rate can mean fewer working enzymes, less available substrate, a missing cofactor, or an inhibitor. The useful question is what changes when you alter one of those conditions. Start with the quantity you actually measured.
Lower the barrier, keep the destination
An enzyme supplies a catalytic route with a lower activation free-energy barrier. Substrate positioning, acid-base chemistry, transient covalent intermediates and transition-state stabilization can contribute. The enzyme returns to a usable state after a catalytic cycle. A transition state is the barrier configuration, not a stable intermediate waiting at the top. Catalytic mechanisms [28]Transition-state definition [20]
Reaction free energy and activation free energy answer different questions. Reaction delta G compares products with reactants under the specified conditions. The activation barrier determines how readily a reaction proceeds along a particular route. A catalyst accelerates approach to equilibrium from either side without changing the equilibrium constant. A negative delta G does not promise a rapid reaction. Catalyst definition [19]
Dashed gray is the uncatalyzed route; solid purple is the catalytic route. Endpoints are shared. Compare the activation barriers; the reaction endpoints have the same free-energy difference. Endpoint thermodynamics [7]Catalytic barrier explanation [28]
Predict the reverse barrier, then lower the catalytic barrier. The reactant and product energies stay fixed.
Transfer. If product instead lay 15 kJ/mol below substrate, a 20 kJ/mol forward barrier would pair with a 35 kJ/mol reverse barrier.
Worked comparison. At a forward barrier of 40 kJ/mol, the reverse barrier is 50 kJ/mol because product lies 10 kJ/mol below reactant. Lowering the forward barrier to 20 also lowers the reverse barrier to 30. The endpoint difference stays -10 kJ/mol.
Try predicting the reverse barrier before changing the model. Then ask whether adding twice as much enzyme should change the endpoint difference. Enzyme amount changes catalytic capacity, not the reaction equilibrium. Temperature, pH and reactant concentrations must be specified when interpreting thermodynamic quantities.
An unfavorable step can proceed when it is chemically coupled to a sufficiently favorable reaction. For a step costing +8 kJ/mol and linked ATP hydrolysis supplying -30 kJ/mol, the overall delta G is -22 kJ/mol under those conditions. ATP in the same tube is insufficient unless a mechanism couples its consumption to synthesis. Breaking a bond alone costs energy. Reaction Gibbs energy concerns the complete reaction, including entropy, solvation and the specified concentrations and solution conditions. Bond accounting alone does not determine it. For several obligatorily linked steps, multiply each reaction energy by its stoichiometric count before adding. Reaction thermodynamics [7]
If only the barrier falls, what happens to the equilibrium product-to-substrate ratio?
It remains unchanged at the same temperature and solution conditions.
Separate substrate supply from catalytic capacity
Measure initial velocity after the brief mixing transient, while product formation is approximately linear and substrate depletion is small. In the steady-state approximation, the concentration of the enzyme-substrate complex is approximately constant over the measurement window. This does not mean substrate and product are at equilibrium. Use substrate well above enzyme concentration and check detector linearity, enzyme stability and required cofactors. Validate the measurement window at each substrate and inhibitor condition. A window that works in one tube need not work across a concentration matrix. Assay controls [5]Steady-state terminology [6]
For a simple Michaelis-Menten response, v = Vmax × S / (Km + S). S and Km share concentration units. Velocity and Vmax share rate units, such as micromol/L/min. Vmax is an asymptotic limiting rate, approached as substrate becomes saturating; no finite substrate concentration gives the exact mathematical limit.
Original live rate plot with a fixed 0-240 micromol/L/min vertical scale. Purple is the selected condition; dashed gray is the uninhibited baseline. The point marks the selected substrate, not an extra fitted observation. IUBMB kinetics [2]
Compare adding substrate with adding active enzyme. Predict which change alters the limiting rate and which leaves kcat unchanged.
Transfer. At substrate 20, reducing active sites to 0.05 micromol/L gives rate 25 micromol/L/min. Each site still has kcat 1000 per minute.
Worked baseline. With 0.1 micromol/L active sites, kcat 1000 per minute and Km 20 micromol/L, Vmax is 100 micromol/L/min. At S 20, v is 50. At S 100, v is 83.33. Doubling active sites doubles both rates while kcat and Km stay fixed.
Km is the substrate concentration at half the limiting rate under the stated Michaelis-Menten conditions. It is not generally a substrate dissociation constant. For the elementary model E + S reversible ES, followed by ES to E + P, Km = (k-1 + kcat)/k1, whereas the ES dissociation constant is k-1/k1. Faster catalytic exit can raise Km without weakening equilibrium binding. Kinetic parameters [2]
Now distinguish the amount of catalyst from the performance of each site. kcat = Vmax / active-site concentration, with reciprocal-time units. If Vmax is 12 micromol/L/min and active sites are 0.02 micromol/L, kcat is 600 per minute, or 10 per second. Use active sites, not all protein in the tube. A partially inactive preparation otherwise looks like an intrinsically slow enzyme. Active-site titration counts catalytically competent sites using a validated stoichiometric probe or catalytic endpoint. Validate its selectivity for that enzyme and cofactor condition. Total protein measurement alone does not supply this count. Inactive protein may still bind an inhibitor, so catalytic normalization and inhibitor-binding mass balance need separate measurements. Active-enzyme assays [1]
At substrate far below Km, v is approximately (kcat/Km) × active sites × S. The ratio kcat/Km is a specificity constant with concentration-inverse time-inverse units. Compare it only under matched conditions. Changing enzyme amount changes total flux capacity but does not, by itself, change this intrinsic ratio.
If active sites double but each site behaves identically, which normalized quantity stays the same?
kcat stays the same because Vmax and active-site concentration double together.
Case 1
Show answer and explanations for case 1
A. One half as large (Why this does not fit)
The raw limiting-rate ratio is 6/12, but the variant tube contains one quarter as many active sites. Normalizing both rates gives twice the turnover per variant site. Equal Km then preserves that twofold advantage at low substrate.
What comparison produces the one-half estimate?
The raw Vmax ratio is 6/12 = 0.5.
What enzyme-loading difference invalidates that estimate?
The variant active-site concentration is 5/20 = one quarter of reference.
What rate ratio follows after correcting that loading difference?
The normalized variant-to-reference rate ratio is 0.5/0.25 = 2.
B. Twice as large (Best answer)
Reference kcat is 12/0.020 = 600 per minute; variant kcat is 6/0.005 = 1200 per minute. Equal Km makes the specificity-constant ratio two. At equal active sites and low substrate, the variant rate is therefore twice reference.
What is reference turnover after converting active sites to micromol/L?
Reference kcat is 12/0.020 = 600 per minute.
What is variant turnover on the same basis?
Variant kcat is 6/0.005 = 1200 per minute.
How does equal Km affect the specificity-constant ratio?
The variant specificity constant is twice reference.
What rate ratio follows at matched active sites and low substrate?
The variant rate is twice the reference rate.
C. Four times as large (Why this does not fit)
The fourfold loading correction is needed, but it must multiply the raw rate ratio of one half. Ignoring that lower measured Vmax overestimates the normalized advantage; the correct ratio is two.
What quantity supplies the factor of four?
The reference-to-variant active-site ratio is 20/5 = 4.
What measured rate ratio must also enter the comparison?
The variant-to-reference Vmax ratio is 6/12 = 0.5.
What is the combined normalized ratio?
The normalized ratio is 4 x 0.5 = 2.
D. The same (Why this does not fit)
Equal Km gives equal fractional saturation at the same substrate concentration. It does not give equal turnover per site. The variant kcat is twice reference, so equal saturation still produces twice the rate at matched active sites.
What does equal Km actually match at the same substrate concentration?
Equal Km matches fractional saturation in this model.
What normalized capacity difference remains?
Variant kcat is 1200 per minute versus reference 600 per minute.
Takeaway: Normalize capacity to active sites before comparing catalytic efficiency.
Infer binding from a perturbation, then test the prediction
A competitive pattern means substrate and inhibitor binding are mutually exclusive in the fitted model. It does not require the inhibitor to look like substrate. An allosteric site is a structural description; an allosteric inhibitor can produce more than one kinetic pattern. Not every enzyme has a separate regulatory site. Mechanism-of-action assays [1]
For the simple reversible mixed model, v = Vmax × S / (alpha × Km + alpha-prime × S). Here alpha = 1 + I/Ki for inhibitor binding to free enzyme, and alpha-prime = 1 + I/Ki-prime for binding to ES. The apparent Vmax is Vmax/alpha-prime and apparent Km is alpha × Km/alpha-prime. Free inhibitor must be approximately known, and binding must be suitably equilibrated.
Predictions within the simple reversible model
Binding pattern
Apparent Km
Apparent Vmax
Binding patternCompetitive, E only
Apparent KmIncreases
Apparent VmaxUnchanged
Binding patternUncompetitive, ES only
Apparent KmDecreases
Apparent VmaxDecreases by the same factor
Binding patternPure noncompetitive, equal E and ES binding
Apparent KmUnchanged
Apparent VmaxDecreases
Binding patternMixed, unequal E and ES binding
Apparent KmCan increase or decrease
Apparent VmaxDecreases
Original state diagram. Solid inhibitor routes are allowed; dashed routes are unavailable in the selected limiting model. The purple output bar shows the computed rate, not measured state occupancy. ESI is assumed inactive. Reversible models [1]
Predict whether raising substrate reduces the inhibited fraction. Change binding permission, then test a new substrate or inhibitor concentration.
Transfer. With E-only binding, substrate 100 and inhibitor 40, the rate is 62.50 micromol/L/min. ES-only binding at the same concentrations gives 31.25.
Worked competitive example. With Vmax 100, Km 20, Ki 20 and I 20 in micromol/L concentration units, S 20 gives v 33.33 micromol/L/min. Raising S to 100 gives v 71.43. The uninhibited rates are 50 and 83.33, so fractional inhibition falls as substrate rises.
Use the binding model to compare E-only, ES-only and both-state inhibition. First predict whether more substrate should reduce the inhibited fraction. Then change substrate and compare the calculated inhibited and uninhibited rates. For a transfer check, double inhibitor as well. Substrate rescue is a model prediction, not a general clinical overdose treatment.
A Lineweaver-Burk plot shows 1/v against 1/S. Its vertical intercept is 1/Vmax and its horizontal intercept is -1/Km. An increased apparent Km puts the horizontal intercept closer to zero. Uncompetitive model lines are parallel; the pure noncompetitive case shares the horizontal intercept. Reciprocal plots magnify low-substrate error, so fit the untransformed rate data for quantitative inference. Fomepizole provides a narrow clinical example of competitive alcohol-dehydrogenase inhibition that reduces toxic-alcohol metabolic activation. Official label [3]
Case 5
Show answer and explanations for case 5
A. 30 micromol/L/min (Why this does not fit)
Thirty is obtained by halving the previous limiting rate of 60. It is not half the previous velocity at S 60, which was 36. Doubling inhibitor changes the factors from 4 and 2 to 7 and 3; the new finite-substrate rate is 22.5.
Which old quantity would halving produce 30?
Halving the old limiting rate of 60 produces 30 micromol/L/min.
What was the old velocity at substrate 60?
The old velocity was 120 x 60/(4 x 20+2 x 60) = 36 micromol/L/min.
What factors must the new finite-substrate calculation use?
The new calculation uses alpha 7 and alpha-prime 3.
B. 22.5 micromol/L/min (Best answer)
The limiting-rate reduction gives alpha-prime = 120/60 = 2. The apparent Km ratio gives alpha = 2 x 40/20 = 4. Doubling inhibitor doubles only the inhibitor-dependent terms, giving 7 and 3. Substitution gives 7200/320 = 22.5 micromol/L/min.
Which factor follows directly from the limiting-rate ratio?
Alpha-prime is 120/60 = 2.
What alpha follows from the apparent Km ratio?
Alpha is 2 x 40/20 = 4.
What factors follow when free inhibitor doubles?
The factors become alpha 7 and alpha-prime 3.
What velocity follows at substrate 60?
The velocity is 120 x 60/(7 x 20+3 x 60) = 22.5 micromol/L/min.
C. 40 micromol/L/min (Why this does not fit)
Forty is the new limiting rate, 120/3. At finite S 60, the alpha Km contribution remains in the denominator, so the velocity is 22.5 rather than the asymptotic limit.
What new factor produces the limiting rate of 40?
The new alpha-prime is 1+2 x (2-1) = 3.
Why is the finite-substrate velocity below 40?
The denominator still contains the positive alpha Km term of 140 micromol/L.
D. 18 micromol/L/min (Why this does not fit)
Doubling the entire factors to 8 and 4 gives 7200/(160+240) = 18. Each factor includes a baseline 1 that does not double. Correct factors 7 and 3 give 22.5.
Which incorrect factors produce 18?
The incorrect factors are alpha 8 and alpha-prime 4.
Which part of an inhibition factor stays fixed when inhibitor doubles?
The uninhibited baseline term 1 stays fixed.
What correct factors result?
The correct factors are alpha 7 and alpha-prime 3.
Takeaway: Mixed inhibition requires separate effects on free and substrate-bound enzyme.
An inhibitor can remain bound long after free drug has fallen. Persistent inhibition at one early washout time therefore does not prove an irreversible chemical lesion. Dilute or separate free inhibitor, verify its residual concentration, and follow recovery while a matched untreated enzyme remains stable. A purified preparation excludes new protein synthesis as the cause of recovery. Delayed recovery supports slow dissociation but does not by itself directly measure a microscopic off-rate; another reversible recovery process can affect the observed trace. Time-dependent inhibition [1]
Tight binding and slow dissociation are distinct concepts. Tight binding can deplete free inhibitor when binding affinity approaches active-site concentration. Slow dissociation describes residence time. Measure active enzyme and use a binding mass balance when added inhibitor no longer approximates free inhibitor. Neither finding alone establishes covalency. IC50 is the inhibitor concentration producing half inhibition under the specified assay conditions. It depends on substrate, target amount and timing. Ki is a parameter of a stated binding model; IC50 is not generally equal to Ki. A binding mass balance accounts for added inhibitor as free inhibitor plus inhibitor bound to every relevant sink. For one-to-one binding, bound inhibitor equals site concentration times fractional occupancy. At unchanged affinity and solution conditions, the same free inhibitor gives the same fractional occupancy; doubling a binding population doubles its bound amount. A catalytically inactive protein pool is not automatically a nonbinding pool.
For an irreversible claim, combine persistent loss after adequate separation with suitable chemical evidence, such as an active-site adduct. Add fresh enzyme to the separated solution to test whether residual inhibitor or an adverse buffer still suppresses activity. Substrate protection may suggest competition for access but cannot, by itself, distinguish reversible binding from irreversible modification.
Mechanism-based inhibition means catalytic processing helps generate the inhibitory species. That label does not replace recovery measurements. Likewise, lower Vmax with unchanged Km is consistent with a normal surviving enzyme fraction after inactivation, but irreversible inhibition has no universal reversible Lineweaver-Burk signature. Ongoing inactivation, heterogeneous sites and substrate protection can change the observations.
Aspirin irreversibly inhibits platelet cyclooxygenase and reduces thromboxane formation. Drug clearance need not restore modified sites. A receptor agonist can test whether downstream signaling remains responsive, while untreated platelets supply functional enzyme. This explanation does not require claiming that platelets have no protein-synthetic machinery. Aspirin mechanism [4]
If washed purified enzyme recovers slowly without synthesis, what does that establish?
At least the recovered fraction was inhibited reversibly under the tested conditions.
Case 7
Show answer and explanations for case 7
A. 70% of original rate; recovery supports reversibility (Why this does not fit)
Seventy percent retains the immediate post-separation active fraction of 20%, then adds 50% fresh capacity. It ignores the later fall in occupancy. The unoccupied original fraction is 60%. Loss of bound X under a trap supports reversible release, so total capacity is 110%.
Which original fraction remains catalytically available at 30 minutes?
The unoccupied original fraction is 100%-40% = 60%.
What fresh capacity must be added?
Fresh sites supply 50% of original untreated capacity.
What total rate follows?
The total rate is 60%+50% = 110%.
B. 110% of original rate; recovery directly measures the microscopic off-rate (Why this does not fit)
The capacity calculation correctly combines 60% original and 50% fresh sites. The inference about a microscopic rate constant overreaches: loss from a target-associated pool can include conformational recovery or multiple bound states. These observations support reversible release but do not identify a unique microscopic dissociation step.
What capacity follows from the two site populations?
The total capacity is 110% of the original untreated preparation.
Why does bound-pool loss not uniquely identify a microscopic off-rate?
Multiple bound states or conformational transitions can contribute to observed target-associated loss.
C. 110% of original rate; recovery supports reversibility (Best answer)
Forty percent occupancy leaves 60% of original sites available. Fresh sites add 50%, and the fresh-enzyme buffer control supports their activity, giving 110%. Declining target-associated X in a synthesis-free preparation supports reversible release of the recovered fraction, without uniquely measuring a microscopic off-rate.
What original catalytic fraction follows from measured occupancy?
The original catalytic fraction is 60%.
What total capacity follows after fresh sites are added?
Total capacity is 60%+50% = 110% of original untreated capacity.
What does declining target-associated X support?
Declining target-associated X supports reversible release of the recovered fraction.
What kinetic quantity remains nonunique?
The microscopic off-rate remains nonunique from these observations alone.
D. 70% of original rate; recovery directly measures the microscopic off-rate (Why this does not fit)
This both miscounts available sites and overinterprets the bound-pool time course. Occupied sites are inactive, so 40% occupancy leaves 60% active rather than 20%. Adding fresh 50% gives 110%; an observed recovery process need not correspond to one microscopic dissociation step.
Which site-counting mistake produces 70%?
Retaining the immediate 20% active fraction gives the obsolete 20%+50% calculation.
What corrected original fraction should be used?
The corrected original active fraction is 60%.
Does the time course identify a unique microscopic transition?
The time course does not identify a unique microscopic transition.
Takeaway: Count available sites; distinguish observed recovery from a uniquely identified microscopic rate constant.
Ask what the enzyme needs and what the assay reports
A cofactor is a nonprotein component required for an enzyme’s catalytic activity. It may be a metal ion or an organic coenzyme. IUPAC cofactor definition [18] For example, pyridoxal phosphate supports aminotransferase chemistry, while NAD and flavins participate in oxidation-reduction reactions. If cofactor addition restores activity immediately without changing protein amount, test cofactor availability before concluding that the catalytic protein is defective. Specific PLP-dependent alanine-transaminase example [12]
An allosteric effector changes activity through regulatory binding. A sigmoidal substrate response does not satisfy the simple Michaelis-Menten equation; describe its half-limiting substrate concentration as S0.5. A regulatory-site mutation that preserves baseline catalysis but abolishes an effector response helps separate regulation from substrate chemistry. A lower S0.5 with the same limiting rate can raise activity at intermediate substrate. Direct effector binding and the activity response are separate measurements. A protein can bind an effector normally yet fail to transmit its regulatory effect. Report specific activity per mass of the stated enzyme population; mixture contributions need an explicit total-mass denominator.
Phosphorylation can alter activity of an existing enzyme without changing its abundance. A rapid effect that persists after small metabolites are separated, then reverses with phosphatase, supports a covalent regulatory mechanism. A nonphosphorylatable site mutant replaces the candidate residue so phosphate cannot be attached there. Check its folding, competent-site count, baseline turnover and substrate response first. Loss of regulation then supports involvement of that site; a mutation that also impairs baseline catalysis cannot by itself isolate the regulatory effect. Removing free ATP does not itself hydrolyze phosphate already attached to protein. Slower changes in transcription, degradation and enzyme abundance are different controls on capacity. Primary phosphorylation study [23]
InterpretationHydrolase; metal or other cofactor needs are still possible
ReactionElectron transfer between reactants
InterpretationOxidoreductase; the electron donor is oxidized
ReactionGroup transfer or intramolecular rearrangement
InterpretationTransferase or isomerase; mutases are intramolecular transferases within isomerases
ReactionNonhydrolytic elimination or addition
InterpretationLyase; often forms or consumes a double bond
ReactionBond formation coupled to nucleotide-triphosphate cleavage
InterpretationLigase; inspect the actual energy-coupling reaction
Synthetase commonly indicates a ligase, but a synthase name alone does not rule out energy input. The current EC system also includes EC7 translocases [14]. Carboxylases and dehydrogenases must be interpreted from their specific reactions rather than a universal suffix rule. Predict what happens when you withhold phosphate versus MgATP from the defined reactions above. Atom tracing identifies a donor, but does not exclude another role for ATP or a metal. An omission experiment must hold the other required components fixed. Some hexokinases accept nucleotide donors other than ATP, so an ATP-depletion prediction must specify which donors are available. Glycogen phosphorylase [15]Hexokinase [16] Water-mediated cleavage can still require a metal; alkaline phosphatase is a zinc-containing example. Official hydrolase entry [17]IUBMB classification [8]
A serum enzyme result is an assay of activity in that specimen. Tissue injury can release intracellular enzyme into blood. That does not show that the intact tissue is running the corresponding metabolic pathway faster. Intracellular flux also depends on substrates, cofactors, competing pathways and demand. A metabolite concentration is a pool size, not a rate. Over a constant-volume interval, net accumulation equals formation minus disposal. Validated tracer analysis follows labeled material over time and accounts for precursor labeling, pool size and competing fates to estimate a particular flux. Label percentage alone does not establish a flux. In a validated early interval with negligible labeled-product loss and one known precursor, labeled-product appearance equals total formation times precursor enrichment. Enrichment 0.4 with labeled appearance 2 micromol/L/min therefore means total formation 5 micromol/L/min. This shortcut fails if precursor labeling changes, other sources contribute, or labeled product is lost. Compare purified active-site-normalized kinetics when the question concerns intrinsic catalysis; use an appropriate cellular flux measurement when the question concerns pathway throughput. ALT assay interpretation [13]
If metal replacement restores a water-cleaving enzyme, does that make it a different reaction class?
No. Cofactor dependence and hydrolytic reaction chemistry describe different properties.
Follow electrons, protons and ATP separately
Oxidation is electron loss; reduction is electron gain. The reducing agent donates electrons and is itself oxidized. The sign and magnitude of an electron-transfer free-energy change depend on the difference between acceptor and donor reduction potentials, rather than the sign of one isolated potential.
NADH-derived electrons enter through complex I. Succinate dehydrogenase is both a TCA-cycle enzyme and respiratory complex II; its bound flavin participates in succinate oxidation. Both routes feed ubiquinone in the inner mitochondrial membrane, then complex III, cytochrome c on the intermembrane-space side, and complex IV, where oxygen is reduced. Complexes I, III and IV support proton pumping; complex II does not. ATP synthase uses proton return to support ATP formation. Complex I reaction [25]Complex III reaction [26]ATP-synthase coupling [27]
Approximate yields often taught as 2.5 ATP per mitochondrial NADH and 1.5 per succinate-linked electron pair depend on coupling assumptions and transport costs. They are not universal measured constants for every cell. Structural and transport costs [22] Other flavoprotein routes can feed ubiquinone without using complex II, so not all flavin-derived electrons should be described as entering through succinate dehydrogenase.
Compare two preparations supplied with adequate oxygen and fuel. ATP-synthase inhibition can raise the proton gradient and slow oxygen use; a protonophore can restore electron flow without restoring coupled ATP synthesis. A terminal respiratory block prevents that recovery. Use membrane potential, oxygen consumption and ATP synthesis together rather than treating one as a substitute for the others.
Uncoupling permits proton return outside ATP synthase. In a suitable experimental range this lowers membrane potential, increases oxygen use and reduces oxidative ATP yield, with energy dissipated as heat. Physiological UCP1-mediated thermogenesis uses regulated proton leak. Direct UCP1 current experiments [21] Toxic chemical uncoupling should not be equated with every hyperthermic syndrome. Severe damage or fuel limitation can also prevent the expected increase in oxygen use.
Cells can partly compensate through glycolytic substrate-level phosphorylation. An ATP concentration that falls only modestly does not prove preserved oxidative ATP synthesis. Follow labeled glucose to lactate, control ATP consumption, and test the effect of selectively reducing glycolytic supply. In a bounded interval, net ATP change equals ATP production minus ATP consumption. Include each source once. In a defined glucose-to-lactate pathway, one glucose gives two lactates and two net ATP, or one ATP per lactate. Correct tracer enrichment before using lactate appearance to estimate this contribution; other lactate sources or altered fates would invalidate that shortcut. Glycolytic ATP stoichiometry [31] Reverse ATP-synthase activity hydrolyzes ATP, so it belongs on the consumption side. Low membrane potential alone does not quantify residual oxidative ATP production. Integrated measurements [9]
For smoke exposure, conventional pulse oximetry can look normal despite carboxyhemoglobin. Co-oximetry measures the relevant hemoglobin species; lactate alone does not distinguish CO from cyanide or other causes of impaired oxygen use. CO can impair both oxygen delivery and cellular utilization. These are useful mechanistic categories, not exclusive labels for CO versus cyanide. Nitrite-induced methemoglobin can worsen already impaired oxygen carriage, so a generic substrate-competition story is not a bedside antidote rule. Assess possible mixed exposure concurrently with urgent treatment. When cyanide poisoning is strongly suspected, treatment must not wait for confirmatory testing. CDC guidance [10]Nitrite precautions [11]
Why can succinate rescue an I-specific defect but fail after a III-specific block?
Succinate bypasses complex I, but its electrons still require complex III to reach oxygen.
When a rate changes, identify the measured compartment and units. Check active enzyme, substrate, cofactors and time. Then choose a perturbation that separates the remaining explanations.
Apply the controls to a new case
These original educational cases use idealized data unless otherwise stated. Predict the result before choosing an option. Explanations remain available for every option, and retries carry no penalty.
Case 2
Show answer and explanations for case 2
A. Km doubles; low-substrate rate increases 1.5-fold (Best answer)
Km includes dissociation plus catalytic exit from ES. Reference Km is 20 micromol/L and variant Km is 40 micromol/L. Their specificity constants are 1 and 1.5 L/micromol/s, so the rate rises 1.5-fold at equal active sites and low substrate.
What is reference Km from the two ES exit rates?
Reference Km is (20+20)/2 = 20 micromol/L.
What is variant Km with faster catalytic exit?
Variant Km is (20+60)/2 = 40 micromol/L.
What is the ratio of variant to reference specificity constants?
The specificity-constant ratio is (60/40)/(20/20) = 1.5.
B. Km is unchanged; low-substrate rate triples (Why this does not fit)
Unchanged binding constants keep Kd at 10 micromol/L. Km also contains catalytic exit, so it doubles. Using kcat alone overlooks the doubled denominator in kcat/Km and predicts too large a low-substrate gain.
Which binding quantity actually stays unchanged?
The ES dissociation constant stays at k-1/k1 = 10 micromol/L.
Why does that not keep Km unchanged?
Km includes kcat, which increases from 20 to 60 per second.
What low-substrate gain remains after accounting for doubled Km?
The low-substrate rate gain is three divided by two = 1.5-fold.
C. Km doubles; low-substrate rate triples (Why this does not fit)
This correctly calculates the Km direction but uses the kcat ratio as the low-substrate rate ratio. Low-substrate performance depends on kcat/Km, so the doubled Km reduces the threefold turnover gain to 1.5-fold.
What rate comparison would a threefold kcat increase support at saturation?
The saturated rate would rise threefold at equal active sites.
Which denominator matters when substrate is far below Km?
The low-substrate rate contains Km through kcat/Km.
What gain follows when that denominator doubles?
The low-substrate gain is 3/2 = 1.5-fold.
D. Km halves; low-substrate rate rises sixfold (Why this does not fit)
Faster ES conversion is not evidence of tighter equilibrium binding. Binding constants stay fixed, while catalytic exit increases the numerator of Km. Km doubles rather than halves, giving a 1.5-fold low-substrate gain.
Does faster catalytic exit demonstrate tighter equilibrium binding?
Faster catalytic exit does not change the supplied binding constants.
What direction does faster exit give Km in this mechanism?
Faster exit raises Km from 20 to 40 micromol/L.
What specificity-constant ratio follows?
The variant-to-reference specificity-constant ratio is 1.5.
Takeaway: Km is a kinetic parameter; binding affinity requires separate evidence.
Using the old apparent Km gives 100 x 50/(30+50) = 62.5. That is the rate at the original inhibitor concentration. Doubling free inhibitor raises the factor from 3 to 5, so apparent Km becomes 50 and the new rate is 50.
Which apparent Km produces 62.5 at substrate 50?
The original apparent Km of 30 micromol/L produces 62.5 micromol/L/min.
What happens to the competitive factor when inhibitor doubles?
The competitive factor rises from 3 to 5.
What rate follows from the new apparent Km?
The new rate is 100 x 50/(50+50) = 50 micromol/L/min.
B. 45.5 micromol/L/min (Why this does not fit)
Doubling the entire initial factor 3 to 6 gives apparent Km 60 and rate 100 x 50/(60+50) = 45.5 micromol/L/min after rounding. The factor includes a baseline 1 that does not double. Only its inhibitor-dependent term doubles, giving factor 5, apparent Km 50 and rate 50.
Which factor error produces the rounded rate 45.5?
Doubling the entire initial factor 3 produces the erroneous factor 6.
Which part of that factor must remain fixed?
The uninhibited baseline term 1 must remain fixed.
What corrected factor applies at twice the inhibitor?
The corrected factor is 1+2 x (3-1) = 5.
What corrected velocity follows at substrate 50?
The corrected velocity is 50 micromol/L/min.
C. 50 micromol/L/min (Best answer)
Unchanged Vmax and tripled apparent Km identify alpha = 3 in the supplied reversible model. Ki is 20/(3-1) = 10 micromol/L. At inhibitor 40, alpha is 5 and apparent Km is 50, so v = 100 x 50/(50+50) = 50 micromol/L/min.
What inhibition factor does the first Km shift imply?
The initial factor is 30/10 = 3.
What Ki follows from inhibitor 20 and factor 3?
Ki is 20/(3-1) = 10 micromol/L.
What apparent Km follows at inhibitor 40?
The new apparent Km is 10 x (1+40/10) = 50 micromol/L.
What rate follows at substrate 50?
The rate is 100 x 50/(50+50) = 50 micromol/L/min.
D. 83.3 micromol/L/min (Why this does not fit)
This is the uninhibited rate, 100 x 50/(10+50). Substrate 50 is finite and does not eliminate competitive inhibition. Using the inhibitor-adjusted Km of 50 gives rate 50.
Which condition does 83.3 represent?
The value 83.3 micromol/L/min represents the uninhibited condition at substrate 50.
Which Km must replace baseline Km after the perturbation?
The new apparent Km is 50 micromol/L.
Takeaway: A new inhibitor concentration requires a new apparent Km.
A. Equal E/ES binding; 30 micromol/L/min (Why this does not fit)
The rate of 30 is the correct ES-selective prediction at the new dose. Equal E/ES binding would preserve Km, whereas measured Km falls threefold. The paired changes identify alpha 1 and alpha-prime 3 before the dose reduction.
What Km response would equal E/ES binding predict?
Equal E/ES binding predicts unchanged apparent Km.
Which measured response rejects that assignment?
Apparent Km falls from 18 to 6 micromol/L.
B. Equal E/ES binding; 22.5 micromol/L/min (Why this does not fit)
A decreased Vmax can suggest equal E/ES binding. Under that interpretation, the initial factors are alpha = alpha-prime = 3; halving free inhibitor correctly changes both factors to 2. The new apparent Vmax is 45 with Km remaining 18, giving 45 x 18/(18+18) = 22.5 micromol/L/min. The dose adjustment is correct within this mistaken mechanism. Equal-state binding is rejected because the measured Km decreases from 18 to 6. The supported ES-selective model instead predicts 30 at the new dose.
Under B's equal-state interpretation, what initial factors follow from the Vmax decrease?
The assumed equal-state factors are alpha = alpha-prime = 90/30 = 3.
Under that interpretation, what factors follow when free inhibitor is halved?
Both assumed factors become 1+(3-1)/2 = 2.
What new apparent Vmax follows under that interpretation?
The assumed new apparent Vmax is 90/2 = 45 micromol/L/min.
What rate follows if Km remains 18 under the equal-state interpretation?
The equal-state prediction is 45 x 18/(18+18) = 22.5 micromol/L/min.
Which supplied finding rejects equal-state binding?
The measured Km falls from 18 to 6, whereas equal-state binding would leave Km unchanged.
What new-dose rate follows from the supported ES-selective model?
The supported ES-selective model predicts 30 micromol/L/min.
C. ES-selective binding; 22.5 micromol/L/min (Why this does not fit)
ES-selective binding fits the proportional falls in Vmax and Km. The numerical prediction ignores the reduced free inhibitor. Halving only the inhibitor-dependent term makes alpha-prime 2, so the new rate is 30 micromol/L/min.
Which binding pattern fits proportional decreases in Vmax and Km?
ES-selective binding fits the proportional decreases.
What part of alpha-prime changes with inhibitor dose?
The inhibitor-dependent term alpha-prime minus 1 halves.
What new velocity follows?
The new velocity is 90 x 18/(18+2 x 18) = 30 micromol/L/min.
D. ES-selective binding; 30 micromol/L/min (Best answer)
Vmax gives alpha-prime 3; the Km ratio then gives alpha 1. This is the ES-selective limiting model. Halving free inhibitor changes alpha-prime to 2, giving 90 x 18/(18+2 x 18) = 30 micromol/L/min. Finite ES-selective inhibitor does not imply complete inhibition at high substrate.
What alpha-prime follows from the initial limiting rates?
Initial alpha-prime is 90/30 = 3.
What alpha follows from the Km shift?
Alpha is 3 x 6/18 = 1.
What alpha-prime follows at half the free inhibitor?
New alpha-prime is 1+(3-1)/2 = 2.
What velocity follows at substrate 18?
The predicted velocity is 30 micromol/L/min.
Takeaway: Infer the binding factor, then change its inhibitor-dependent part before predicting a new rate.
The fourfold capacity reduction gives alpha-prime 4. Unchanged Km makes alpha 4 as well. Halving inhibitor gives both factors 2.5, while doubling sites makes uninhibited Vmax 240. The new rate is 240 x 45/[2.5 x (15+45)] = 72.
What does unchanged Km imply once alpha-prime is 4?
Alpha must also be 4 in the fitted mixed model.
What equal factor follows when inhibitor is halved?
The new factor is 1+(4-1)/2 = 2.5.
What uninhibited capacity follows when active sites double?
The new uninhibited Vmax is 240 micromol/L/min.
What velocity follows at substrate 45?
The velocity is 240 x 45/(2.5 x 60) = 72 micromol/L/min.
B. 90 micromol/L/min (Why this does not fit)
Halving the whole factor 4 to 2 gives 240 x 45/(2 x 60) = 90. Only its inhibitor-dependent part halves; the baseline 1 remains. The correct factor is 2.5 and the rate is 72.
What factor would produce 90?
An incorrectly halved factor of 2 would produce 90 micromol/L/min.
Why must the factor instead be 2.5?
The new factor retains baseline 1 plus half of the original inhibitor term 3.
C. 36 micromol/L/min (Why this does not fit)
This correctly halves inhibitor but leaves enzyme loading unchanged, giving 120 x 45/(2.5 x 60) = 36. The new tube has twice as many active sites, so its rate doubles to 72.
Which loading assumption produces 36?
The calculation of 36 retains the original Vmax of 120 micromol/L/min.
What stated change corrects that loading assumption?
The new tube contains twice as many active sites.
D. 45 micromol/L/min (Why this does not fit)
Keeping the original fourfold suppression after doubling enzyme gives 240 x 45/(4 x 60) = 45. That ignores the halved free inhibitor. Reversibility and the fitted model require the factor to fall to 2.5.
Which unchanged factor produces 45?
Retaining the old factor of 4 produces 45 micromol/L/min.
What perturbation requires a different factor?
Halving free inhibitor reduces the factor to 2.5.
Takeaway: Infer equal binding factors from kinetics before predicting a new enzyme and inhibitor condition.
Forty counts only the new sites, using turnover 80/10 = 8 rate units per nmol/L. Four original competent sites remain, contributing 32, so total capacity is 72.
Which enzyme population produces the estimate of 40?
The 5 nmol/L fresh sites contribute 5 x 8 = 40 micromol/L/min.
What original capacity must be added?
The 4 nmol/L surviving sites contribute 32 micromol/L/min.
B. 72 micromol/L/min (Best answer)
Original kcat is 80/0.010 = 8000 per minute, equivalent to 8 rate units per nmol/L competent sites. Four surviving plus five fresh sites give 9 nmol/L competent sites. The measured negligible free inhibitor and stable-buffer controls support activity of the added sites under these conditions. Total capacity is 8000 x 0.009 = 72 micromol/L/min.
What turnover follows after converting competent sites to micromol/L?
Original kcat is 80/0.010 = 8000 per minute.
What do the filtrate and buffer controls support about the added fresh sites?
The controls oppose continuing inhibition by the final soluble environment.
How many competent sites should be present after addition?
The preparation should contain 4+5 = 9 nmol/L competent sites.
What limiting rate follows?
The predicted limiting rate is 9 x 8 = 72 micromol/L/min.
C. 48 micromol/L/min (Why this does not fit)
This applies the original 40% active fraction to all 15 nmol/L protein sites, including the fresh enzyme. Stable adducts remain on the originally exposed sites, while negligible residual inhibitor does not predict modifying 60% of the new sites. The correct total is 72.
Why should the original inactive fraction not be imposed on fresh sites?
The fresh sites were not exposed to the adduct-forming condition.
D. 120 micromol/L/min (Why this does not fit)
This treats all original and fresh protein as competent, using 15 x 8. The six nmol/L stably modified original sites do not regain activity simply because fresh enzyme is added. Nine nmol/L competent sites give 72.
What protein population is counted by 120?
The estimate counts all 15 nmol/L original plus fresh sites as competent.
Which population must be excluded from catalytic capacity?
The 6 nmol/L stably modified original sites must be excluded.
Takeaway: Count surviving and replacement competent sites separately from total protein.
A. Output 40%; direct agonist aggregation is impaired (Why this does not fit)
The mixture calculation is correct: 0.75 x 20+0.25 x 100 = 40%. Normal PGH2-driven thromboxane production and aggregation place the measured defect before the supplied intermediate, with downstream signaling usable. A direct receptor agonist bypasses the newly blocked synthesis and should preserve aggregation.
What output follows from the mixture weights?
The mixture produces 40% of equal-count untreated thromboxane.
What does PGH2-supported aggregation establish?
The downstream synthesis-to-aggregation pathway is functional in this assay.
Does a direct receptor agonist require endogenous thromboxane synthesis?
A direct receptor agonist bypasses endogenous thromboxane synthesis.
B. Output 80%; direct agonist aggregation is preserved (Why this does not fit)
The agonist prediction follows from preserved downstream function. Eighty percent reverses the mixture proportions, assigning 75% to untreated platelets. The actual mixture is 75% exposed, giving 40%.
Which reversed weights produce 80%?
Using 75% untreated and 25% exposed produces 80%.
Which population actually accounts for 75%?
Exposed platelets account for 75% of the mixture.
C. Output 80%; direct agonist aggregation is impaired (Why this does not fit)
The output reverses the mixture weights, and the signaling prediction confuses synthesis with response to an already supplied agonist. PGH2-supported aggregation shows that downstream signaling can operate. The correct predictions are 40% synthesis and preserved direct-agonist aggregation.
What weighted synthesis follows from 75% exposed platelets?
Weighted synthesis is 40% of untreated output.
Which supplied result opposes a downstream aggregation defect?
PGH2 restores aggregation in the exposed preparation.
Which new stimulus bypasses the synthesis block?
The direct receptor agonist bypasses the synthesis block.
D. Output 40%; direct agonist aggregation is preserved (Best answer)
The additive output is 0.75 x 20+0.25 x 100 = 40%. PGH2 restores synthesis and aggregation, placing the exposure-associated deficit upstream of that intermediate. A direct receptor agonist therefore bypasses complete endogenous synthesis blockade. Mixing supports no detectable transferable effect under the tested conditions, not proof that no soluble effect could ever occur.
What new mixture output follows from additive synthesis?
The new mixture output is 40%.
Where does PGH2 rescue place the measured exposure-associated deficit?
The deficit lies upstream of PGH2-dependent thromboxane production.
What aggregation response should direct receptor stimulation retain?
Direct receptor stimulation should retain aggregation despite synthesis blockade.
Takeaway: A downstream agonist can bypass synthesis failure when the downstream response remains functional.
Initially, half occupancy binds 10 nmol/L to competent sites; inactive target binds another 6. Free inhibitor is therefore 18-10-6 = 2 nmol/L. The same fractional occupancy requires that same free concentration, while doubling each protein pool doubles its bound amount. The new total is 2+20+12 = 34 nmol/L.
How much inhibitor is initially bound to competent sites?
Competent sites initially bind 20 x 0.5 = 10 nmol/L.
What initial free inhibitor follows from mass balance?
Free inhibitor is 18-10-6 = 2 nmol/L.
How much inhibitor binds the doubled inactive pool at that free concentration?
The doubled inactive pool binds 12 nmol/L.
What new added concentration supplies both bound pools and free inhibitor?
The new added concentration is 20+12+2 = 34 nmol/L.
B. 22 nmol/L (Why this does not fit)
This keeps the correctly inferred free concentration of 2 and adds 20 bound to competent sites, but omits inactive target. The inactive protein demonstrably binds 6 in the original tube; doubling it at the same free concentration requires 12 more, bringing the total to 34.
Which bound pool is omitted by 20+2?
The inactive-target inhibitor pool is omitted.
What measured result shows that pool cannot be ignored?
The original inactive target binds 6 nmol/L inhibitor.
What total results when its doubled binding is included?
Including 12 nmol/L inactive-target binding gives 34 nmol/L.
C. 32 nmol/L (Why this does not fit)
This correctly doubles the two bound pools to 20 and 12 but treats added inhibitor as entirely bound. The initial mass balance establishes 2 nmol/L free inhibitor, which must remain available for the same occupancy. The required total is 34.
What does 32 account for?
The value 32 accounts for the two bound inhibitor pools.
What unbound term is required by the initial balance?
The initial balance requires 2 nmol/L free inhibitor.
D. 42 nmol/L (Why this does not fit)
This assigns all 20 nmol/L inactive sites full occupancy while retaining free inhibitor 2 and competent binding 20. Inactive occupancy was 6/10, not one. At unchanged affinity and the same free concentration it remains 60%, giving inactive binding 12 and total 34.
What inactive occupancy is assumed by 42?
The estimate assumes 100% occupancy of inactive target.
What inactive occupancy is actually measured?
Measured inactive occupancy is 6/10 = 60%.
What amount binds after that pool doubles?
The doubled inactive pool binds 12 nmol/L.
Takeaway: A target-dose prediction needs free inhibitor plus every independently characterized binding sink.
A. Initially 9/13; afterward 4/7 (Why this does not fit)
The second value correctly accounts for both ATP and free compound after the perturbation. The initial 9/13 is treated velocity divided by Vmax, rather than divided by control velocity. The matched control is itself below Vmax; the initial treated/control ratio is 10/13.
What denominator produces the initial 9/13?
Vmax as denominator produces 360/(160+360) = 9/13.
What denominator does the question require?
The question requires uninhibited velocity at the same ATP concentration.
What initial ratio follows with that denominator?
The initial ratio is (40+360)/(160+360) = 10/13.
B. Initially 9/13; afterward 2/5 (Why this does not fit)
The first value uses Vmax instead of the matched control rate. The second retains the old apparent Km 160 despite the measured fall in free compound. Correct normalization gives 10/13 initially; halving compound makes apparent Km 100 and the new ratio 4/7.
Which initial reference rate is required?
The required reference is uninhibited velocity at ATP 360.
What post-perturbation fact invalidates retaining Km 160?
Free compound falls from 6 to 3 micromol/L.
What post-perturbation apparent Km follows?
The new apparent Km is 40 x [1+(4-1)/2] = 100 micromol/L.
C. Initially 10/13; afterward 4/7 (Best answer)
The initial treated/control ratio is (40+360)/(160+360) = 10/13. The original factor is 4, so halving free compound makes it 1+3/2 = 2.5 and apparent Km 100. At ATP 40, the new matched-control ratio is (40+40)/(100+40) = 4/7.
What initial normalized ratio follows at ATP 360?
The initial treated-to-control ratio is 10/13.
What factor follows when free compound halves?
The competitive factor becomes 2.5.
What new apparent Km follows?
The new apparent Km is 100 micromol/L.
What new normalized ratio follows at ATP 40?
The new treated-to-control ratio is 80/140 = 4/7.
D. Initially 10/13; afterward 2/5 (Why this does not fit)
The initial ratio is correct. The later 2/5 would follow if free compound remained 6 and apparent Km remained 160. Measured free compound instead halves, decreasing apparent Km to 100, so the later ratio is 4/7.
What condition would make the later ratio 2/5?
Unchanged free compound 6 would retain apparent Km 160.
What new free concentration must be used?
The measured new free concentration is 3 micromol/L.
What corrected later ratio follows?
The corrected later ratio is 4/7.
Takeaway: A cellular substrate change can coincide with altered free drug; recompute both before normalizing to control.
A. Formation 8 then 2 micromol/L/min; raising methanol weakens fractional inhibition (Why this does not fit)
The substrate prediction fits the Km/Vmax pattern. The formation estimates confuse net accumulation with formation. Disposal must be added back, giving formation 11 before and 5 during intervention.
What do the measured rates 8 and 2 describe?
The rates 8 and 2 describe net formate accumulation.
What formation rates follow after adding measured disposal?
The formation rates are 11 and 5 micromol/L/min.
B. Formation 11 then 5 micromol/L/min; raising methanol weakens fractional inhibition (Best answer)
Formation equals accumulation plus disposal, giving 8+3 = 11 and 2+3 = 5 micromol/L/min. The purified unchanged-Vmax, raised-Km pattern supports competitive inhibition, whose inhibited fraction falls with more substrate. Unchanged renal elimination does not imply unchanged total parent clearance; the substrate prediction applies only to the purified in-vitro assay.
What was formate formation before intervention?
Formate formation was 8+3 = 11 micromol/L/min.
What is formate formation during intervention?
Formate formation is 2+3 = 5 micromol/L/min.
Which substrate response follows from the purified kinetic pattern?
Raising methanol weakens fractional inhibition in the fitted competitive model.
C. Formation 11 then 5 micromol/L/min; raising methanol strengthens fractional inhibition (Why this does not fit)
The mass balance is correct. Strengthening inhibition with substrate instead fits the ES-selective limiting pattern, which lowers both apparent Km and Vmax. The observed unchanged Vmax and raised Km support competitive weakening.
Which reversible state-selective model can strengthen inhibition with substrate?
The ES-selective model can strengthen inhibition as substrate increases.
What fitted observation defeats that model here?
Apparent Km rises while Vmax remains unchanged.
D. Formation 8 then 2 micromol/L/min; raising methanol strengthens fractional inhibition (Why this does not fit)
This both treats accumulation as formation and assigns the wrong kinetic pattern. Adding disposal gives 11 then 5. The measured competitive pattern predicts weaker fractional inhibition at higher methanol.
Which disposal term was omitted from the formation calculation?
The calculation omitted disposal of 3 micromol/L/min in each interval.
Which pattern follows from raised Km with unchanged Vmax?
The supplied fit identifies the competitive limiting pattern.
What substrate response follows?
Higher methanol weakens fractional inhibition.
Takeaway: Metabolite accumulation equals formation minus disposal; measure both before assigning the cause.
A. Patient rate one half of reference; normal PLP affinity not established (Why this does not fit)
The raw PLP-saturated rate ratio is 3/6, but the patient preparation contains half the competent sites. Both enzymes turn over 600 substrates per site per minute. The normalized ratio is one; a saturating endpoint does not establish normal PLP affinity.
What loading difference accompanies the raw one-half rate?
The patient tube contains half as many competent sites.
What normalized rate ratio follows?
The matched-site rate ratio is one.
B. Patient rate equal to reference; normal PLP affinity established (Why this does not fit)
Matched-site turnover is indeed equal after PLP saturation. However, saturating PLP can mask altered cofactor affinity; the low-PLP responses differ and no cofactor-binding constant is supplied. Equality at saturation does not establish normal PLP affinity.
What aspect of catalysis is equal after PLP saturation?
Turnover per competent site is equal at 600 per minute.
Why does that not establish normal PLP affinity?
Saturating PLP can conceal a difference in PLP affinity.
C. Patient rate one half of reference; normal PLP affinity established (Why this does not fit)
This compares raw rates despite unequal competent sites and treats saturation rescue as a binding measurement. Normalization gives equal rates, while the supplied data do not establish equal PLP affinity.
Which normalization is missing from the half-rate claim?
The claim omits normalization to 5 versus 10 nmol/L competent sites.
What cofactor conclusion remains unresolved?
The relative PLP affinity remains unresolved.
D. Patient rate equal to reference; normal PLP affinity not established (Best answer)
At PLP saturation, patient kcat is 3/0.005 = 600 per minute and reference kcat is 6/0.010 = 600 per minute. Equal competent sites therefore give equal saturated rates. The unequal low-PLP response shows why this conclusion must be limited to PLP-replete catalysis; it does not exclude altered cofactor affinity.
What is patient turnover after PLP saturation?
Patient kcat is 3/0.005 = 600 per minute.
What is reference turnover after PLP saturation?
Reference kcat is 6/0.010 = 600 per minute.
What matched-site rate ratio follows?
The predicted matched-site rate ratio is one.
Which intrinsic property remains unmeasured?
PLP binding affinity remains unmeasured.
Takeaway: Equal cofactor-replete turnover does not establish equal cofactor affinity.
A. Wild type above 50 units/mg; regulatory binding fails to produce the normal activity response in the variant (Best answer)
Substrate 3 exceeds wild-type S0.5 1, so wild-type activity exceeds half its own limiting specific activity. The variant still binds M to the same measured extent, yet its substrate response does not shift. The defect therefore concerns the functional response to occupied regulatory sites rather than absence of measured M binding.
What activity bound follows from wild-type S0.5 1 at substrate 3?
Wild-type activity exceeds 50 units per mg of wild-type enzyme.
Does the variant lose measured M occupancy?
Variant M occupancy remains 90%, equal to wild type.
What regulatory function is impaired despite occupancy?
The variant fails to translate regulatory-site occupancy into the normal substrate-response shift.
B. Wild type above 50 units/mg; the variant fails to bind M (Why this does not fit)
The wild-type bound is correct. Failure to respond can tempt a loss-of-binding explanation, but the direct assay finds equal 90% M occupancy. Binding occurs; the measured functional response to binding is lost.
What makes loss of binding a tempting explanation?
A missing effector response can result from missing effector binding.
Which result defeats that explanation here?
Direct binding measures equal 90% regulatory-site occupancy in both proteins.
C. Wild type below 50 units/mg; the variant fails to bind M (Why this does not fit)
This retains the wild-type baseline S0.5 despite its measured shift to 1 and equates loss of regulation with loss of binding. At substrate 3 wild type is above half its own limit, and the variant retains measured M occupancy.
Which S0.5 applies to wild type after adding M?
Wild-type S0.5 with M is 1 mmol/L.
What activity bound follows at substrate 3?
Wild-type activity is above 50 units/mg.
What variant binding result must be retained?
Variant M-site occupancy remains 90%.
D. Wild type below 50 units/mg; regulatory binding fails to produce the normal activity response in the variant (Why this does not fit)
The binding-versus-response conclusion fits equal M occupancy with a lost variant shift. The wild-type bound incorrectly uses its no-M S0.5 of 6. With M, S0.5 is 1 and substrate 3 places wild type above half the 100-unit/mg limit.
Which condition does the wild-type S0.5 of 6 describe?
S0.5 6 describes wild type without M.
Which value applies in the requested assay?
S0.5 1 applies to wild type with M.
Takeaway: Measure regulatory binding separately from the activity response it produces.
A. Ratio 2.4; wild-type activity returns to 100 units (Why this does not fit)
The ratio is correctly 60/25 = 2.4. Recovery to 100 mistakes free-ATP removal for removal of covalently bound phosphate. Inhibition already persists after small-metabolite separation, while phosphatase reverses it. ATP scavenging should leave activity near 25.
What ratio follows from measured regulated activities?
The variant-to-wild-type ratio is 60/25 = 2.4.
Which observation rejects soluble ATP as the continuing inhibitory agent?
Wild-type inhibition persists after small metabolites are removed.
What modification remains after ATP scavenging?
Protein-bound phosphate remains after ATP scavenging.
B. Ratio 4.0; wild-type activity returns to 100 units (Why this does not fit)
The ratio uses the wild-type baseline 100 as if it were the variant baseline, which is actually 60. The recovery prediction also treats ATP removal as dephosphorylation despite persistence after metabolite separation. The supported predictions are ratio 2.4 and wild-type activity 25.
Which treatment actually reverses the persistent inhibition?
Phosphatase reverses persistent inhibition while removing protein-bound phosphate.
Does the specified scavenger perform that reaction?
The specified scavenger does not remove protein-bound phosphate.
C. Ratio 2.4; wild-type activity remains near 25 units (Best answer)
The variant retains its measured baseline 60, so its regulated ratio to wild type is 60/25 = 2.4. Persistence after metabolite separation and phosphatase reversal support covalent regulation of existing X. Removing only free ATP does not erase the modification, so activity should remain near 25 under the specified assay.
What ratio follows using the variant own baseline?
The regulated ratio is 2.4.
What mechanism is supported by persistence plus phosphatase reversal?
The controls support regulation by protein-bound phosphate.
What wild-type activity follows when only free ATP is removed?
Wild-type activity should remain near 25 units.
D. Ratio 4.0; wild-type activity remains near 25 units (Why this does not fit)
The persistence prediction correctly distinguishes free ATP from protein-bound phosphate. The ratio wrongly assumes the mutation preserves wild-type baseline turnover. Measured variant capacity is 60, so the correct ratio is 2.4.
What capacity is actually measured for the variant?
Variant baseline capacity is 60 units.
What denominator applies after kinase treatment?
Wild-type activity after kinase treatment is 25 units.
What corrected ratio follows?
The corrected ratio is 60/25 = 2.4.
Takeaway: Removing a phosphate donor does not remove a phosphate already attached to protein.
A. Formation ratio 0.5; disposal ratio 3 (Why this does not fit)
The disposal ratio is correct only after precursor correction and mass balance. Formation ratio 0.5 uses raw labeled appearance 1.5/3, ignoring that patient precursor labeling is only one third of reference. Correct formation is 1.5/0.25 = 6 versus 3/0.75 = 4, giving ratio 1.5.
What does the raw ratio 1.5/3 compare?
The raw ratio compares labeled-product appearance rather than total formation.
What formation rates follow after precursor correction?
Total formation is 6 in patient cells and 4 micromol/L/min in reference cells.
What formation ratio follows?
The formation ratio is 6/4 = 1.5.
B. Formation ratio 1.5; disposal ratio 3 (Best answer)
Correcting label appearance for precursor enrichment gives formation 6 versus 4 micromol/L/min. Disposal equals formation minus net accumulation, giving 6-0 = 6 versus 4-2 = 2. Ratios are therefore 1.5 for formation and 3 for disposal. Serum ALT is a different specimen assay and is not used to calculate either cellular flux.
What patient formation rate follows from precursor enrichment?
Patient formation is 1.5/0.25 = 6 micromol/L/min.
What reference formation rate follows?
Reference formation is 3/0.75 = 4 micromol/L/min.
What formation ratio follows?
The patient-to-reference formation ratio is 1.5.
What patient disposal follows from zero net accumulation?
Patient disposal is 6 micromol/L/min.
What reference disposal follows from net accumulation 2?
Reference disposal is 4-2 = 2 micromol/L/min.
What disposal ratio follows?
The patient-to-reference disposal ratio is 6/2 = 3.
C. Formation ratio 1.5; disposal ratio 1.5 (Why this does not fit)
The precursor-corrected formation ratio is correct. Equating the disposal ratio to it assumes both product pools are at steady concentration. Reference pyruvate instead accumulates at 2, so disposal is only 4-2 = 2, compared with patient disposal 6. The disposal ratio is 3.
What unstated condition would allow formation to equal disposal in both preparations?
Both preparations would need zero net accumulation.
Which supplied observation violates that condition?
Reference pyruvate accumulates at 2 micromol/L/min.
What corrected disposal ratio follows?
The corrected disposal ratio is 6/(4-2) = 3.
D. Formation ratio 0.5; disposal ratio 1.5 (Why this does not fit)
This option treats labeled appearance as total formation but retains the mass balance. Without enrichment correction, the formation ratio is 1.5/3 = 0.5. Subtracting the stated accumulation then gives apparent disposal 1.5-0 = 1.5 and 3-2 = 1, giving disposal ratio 1.5. The error is the uncorrected formation inputs, not omission of accumulation. Correcting enrichment gives formation 1.5/0.25 = 6 and 3/0.75 = 4 micromol/L/min, a ratio of 1.5. Corrected disposal is 6-0 = 6 and 4-2 = 2, a ratio of 3.
What formation ratio results if labeled appearance is incorrectly treated as total formation?
The uncorrected formation ratio is 1.5/3 = 0.5.
What disposal ratio results when mass balance is applied to those uncorrected inputs?
The uncorrected disposal ratio is (1.5-0)/(3-2) = 1.5.
Which supplied measurement requires correction of the formation inputs?
The unequal alanine precursor enrichments, 25% and 75%, require correction of labeled appearance.
What total formation rates follow after correcting precursor enrichment?
Corrected formation rates are 1.5/0.25 = 6 for patient cells and 3/0.75 = 4 micromol/L/min for reference cells.
What corrected formation ratio follows?
The corrected patient-to-reference formation ratio is 6/4 = 1.5.
What disposal rates follow from corrected formation minus accumulation?
Corrected disposal rates are 6-0 = 6 for patient cells and 4-2 = 2 micromol/L/min for reference cells.
What corrected disposal ratio follows?
The corrected patient-to-reference disposal ratio is 6/2 = 3.
Takeaway: Correct precursor labeling before calculating flux, then distinguish formation from disposal.
A. Use 0-15-second slopes for these described assays (Why this does not fit)
This early window minimizes depletion and remains within detector range, but inhibitor binding has not equilibrated. Its slopes cannot be treated as equilibrated steady-state inhibition measurements.
Which condition fails during 0-15 seconds?
Inhibitor binding is not yet equilibrated.
What earliest completed-equilibration time is supplied?
Binding equilibration is complete at 20 seconds.
B. Use 50-70-second slopes for these described assays (Why this does not fit)
Binding has equilibrated and substrate depletion is still small, but product reaches 8 micromol/L above the detector’s validated ceiling of 6. A visually straight signal does not validate concentration-proportional detection.
Which measurement limit fails in the 50-70-second interval?
Product rises above the detector’s linear ceiling of 6 micromol/L.
Which window instead meets both timing and detector limits?
The 25-45-second window meets both limits.
C. Use 80-110-second slopes for these described assays (Why this does not fit)
This later window is post-equilibration but exceeds the detector range throughout and reaches 15% substrate consumption. Those conditions defeat a conventional initial-rate fit despite visually constant signal slopes.
What substrate fraction has been consumed by product 30?
Substrate consumption is 30/200 = 15%.
Which interval avoids both excessive product and pre-equilibration measurement?
The 25-45-second interval avoids both limitations.
D. Use 25-45-second slopes for these described assays (Best answer)
The first 20 seconds are needed for inhibitor equilibration. During 25-45 seconds, product remains 2-4 micromol/L, inside the calibrated range, with no more than 2% substrate consumption. This interval supports an equilibrated initial-rate comparison; time-dependent binding should still be analyzed separately when relevant. This window must be revalidated at other substrate or inhibitor concentrations.
Which candidate intervals begin after binding equilibration?
The 25-45, 50-70 and 80-110-second intervals begin after equilibration.
Which of those remains entirely within detector linearity?
The 25-45-second interval remains entirely below 6 micromol/L product.
What maximum substrate loss occurs in that interval?
Maximum substrate loss is 4/200 = 2%.
Which interval should supply the fitted slopes?
The 25-45-second interval should supply slopes only for the described assays.
Takeaway: Choose the interval where binding, substrate and detector conditions are valid together.
A. Little further rate increase; the first plateau reflects catalytic capacity (Best answer)
The substrate plateau with preserved enzyme-dose response supports near-saturation of functional sites. Product controls show the detector reads beyond 8. At fixed enzyme, more substrate should therefore cause little further rate increase within the tested stable regime.
What does the rate increase to 16 show about a detector ceiling at 8?
The measured increase excludes a detector ceiling at 8.
What does the substrate plateau then support?
The substrate plateau supports near-saturation of functional sites.
What response is predicted at fixed enzyme with more substrate?
Little further rate increase is predicted.
B. Rate doubles to 16 because the assay remains substrate limited (Why this does not fit)
Proportional substrate effects are expected well below Km. A high-substrate plateau instead indicates near-saturation, while the enzyme-dose response shows that more enzyme can still add capacity. Doubling substrate should not double the rate in this regime.
Which regime would support doubling rate by doubling substrate?
The low-substrate regime far below Km would support that proportional response.
What measured pattern argues against that regime?
The measured high-substrate response has already plateaued.
C. Rate remains 8 because the detector cannot read higher values (Why this does not fit)
A detector ceiling is a plausible cause of an apparent plateau. Here both the enzyme-doubling response to 16 and product calibration through 25 reject a ceiling at 8, so the unchanged-rate prediction has the wrong explanation.
What instrumental defect could produce a false plateau?
Detector saturation could produce a false plateau.
What two controls reject a ceiling at 8?
The enzyme-dose result and product standards demonstrate measurable values above 8.
D. Rate falls below 8 because excess substrate inhibits turnover (Why this does not fit)
Substrate inhibition can cause a downturn at high substrate. The supplied series shows a plateau rather than a downturn, with functional enzyme-dose scaling. No high-substrate inhibitory pattern is supplied, so near-saturation is the supported prediction within this regime.
What substrate-response shape would support substrate inhibition?
A reproducible downturn at increasing substrate would support substrate inhibition.
What shape is actually reported?
The reported response is a plateau rather than a downturn.
Takeaway: Validate the measurement ceiling before interpreting a kinetic plateau.
A. Two donors per P; Y measurements justify assigning the energy (Why this does not fit)
Two donors leave 17-14 = +3 kJ/mol P, still unfavorable. Continued donor turnover without A and no detectable P above background do not demonstrate coupling in Y, despite its ability to use an activated intermediate. Three linked donors are the minimum; Y does not demonstrate that linked reaction.
What net energy follows with two linked donors?
The net energy is +3 kJ/mol P.
What Y observation challenges linkage to A consumption?
Donor turnover continues unchanged when A is omitted.
Does the Y assay demonstrate net A-to-P synthesis?
The Y assay shows no P above enzyme-free background.
B. Three donors per P; Y measurements justify assigning the energy (Why this does not fit)
Three linked donors give 17-21 = -4 kJ/mol P. The Y conclusion nevertheless mistakes donor turnover for productive coupling. Donor consumption is independent of A in the supplied comparison, and no net P is detected; the activated-intermediate control shows the product assay can function.
What net energy follows with three linked donors?
The linked net energy is -4 kJ/mol P.
What does the activated-intermediate control establish?
The control establishes that Y can perform the downstream P-forming reaction.
Why is measured donor consumption insufficient for Y?
Measured donor consumption is not accompanied by detectable A-to-P synthesis.
C. Three donors per P; Y measurements do not justify assigning the energy (Best answer)
Two donors leave +3 kJ/mol P; three give -4, so three is the minimum favorable whole-number stoichiometry. Y consumes donor without A and makes no P above background despite a functional downstream assay. Those observations do not demonstrate an energy-coupled A-to-P reaction; equal-time energy release cannot simply be added to synthesis.
What energy remains with two linked donors?
Two linked donors leave +3 kJ/mol P.
What is the first favorable whole-number donor count?
Three linked donors give -4 kJ/mol P.
What does A-independent donor turnover indicate in Y?
The observed donor turnover can occur without A-to-P synthesis.
What thermodynamic assignment is justified for Y?
Assigning donor hydrolysis energy to A-to-P synthesis in Y is not justified by these data.
D. Two donors per P; Y measurements do not justify assigning the energy (Why this does not fit)
The Y interpretation correctly withholds a coupling claim. The stoichiometry rounds 17/7 downward, leaving a positive net energy of +3. Favorability requires the next whole donor count, three, with net -4.
What arithmetic error gives two donors?
Rounding 17/7 downward gives two donors.
What sign does the two-donor net energy retain?
The two-donor net energy remains positive at +3 kJ/mol P.
What donor count first makes the sum negative?
Three donors first make the sum negative.
Takeaway: Thermodynamic sums require a demonstrated or specified linked reaction.
ATP depletion can affect enzymes through roles other than donating product phosphate. Donor labeling alone would not exclude such a requirement for X. Here a separate defined-buffer ATP-omission control establishes X activity without ATP, while Y loses its only available nucleotide donor. X continues and Y decreases.
Can donor labeling alone exclude every other ATP requirement?
Donor labeling alone cannot exclude ATP roles outside phosphate donation.
Which supplied control establishes ATP-independent X activity?
The defined-buffer ATP-omission control establishes ATP-independent X activity.
B. X continues; Y decreases (Best answer)
Tracing assigns inorganic phosphate to X and ATP terminal phosphate to Y. The independent ATP-omission control, not the tracer assignment alone, establishes that X can operate without ATP in this defined system. Y has no alternative nucleotide donor available, so selective ATP depletion decreases Y while X continues.
Which pool supplies X product phosphate?
The inorganic-phosphate pool supplies X product phosphate.
Which pool supplies Y product phosphate?
The ATP terminal-phosphate pool supplies Y product phosphate.
Which evidence establishes that X needs no ATP for another role here?
The separate defined-buffer ATP-omission assay establishes that point.
Which reaction loses its donor after selective ATP depletion?
Reaction Y loses its phosphate donor.
C. X decreases; Y continues (Why this does not fit)
This reverses the measured donor assignments. X uses the preserved inorganic-phosphate pool, whereas Y uses the depleted ATP pool. The expected pattern is X continuing and Y decreasing.
Which labeled pool actually enters Y product?
The ATP terminal-phosphate pool enters Y product.
What happens to that pool in the perturbation?
The perturbation depletes ATP.
D. Both X and Y continue (Why this does not fit)
Unchanged enzyme abundance preserves potential capacity but cannot replace a missing reactant. X retains inorganic phosphate; Y loses ATP without regeneration. Y therefore decreases during the initial assay.
Which required donor remains available to X?
Inorganic phosphate remains available to X.
Why is unchanged Y protein insufficient to maintain Y flux?
Y lacks its required ATP donor.
Takeaway: A traced donor identifies an atom source; separate controls establish other cofactor requirements.
A. Hydrolase; supply MgATP while keeping zinc absent (Why this does not fit)
Water-mediated monoester cleavage identifies a hydrolase. MgATP may seem a general way to restore a low-activity enzyme, but the controlled difference is lost zinc, with other cofactors adequate and folding retained. A zinc add-back tests the implicated missing component directly.
Which controlled component is absent from the low-activity preparation?
Bound zinc is absent from the low-activity preparation.
Which addition directly tests that component?
Zinc add-back directly tests the missing component.
B. Transferase; restore zinc at matched free-metal conditions (Why this does not fit)
Zinc restoration is the appropriate targeted test. The classification incorrectly treats any phosphate reaction as transferase activity. This measured reaction uses water to release free phosphate and alcohol, identifying hydrolysis; transferase acceptors are not restricted to organic molecules.
What makes a phosphate-transfer classification tempting?
The substrate and product both concern phosphate chemistry.
What measured chemistry decides the class here?
Water-mediated release of free phosphate decides the hydrolase classification.
C. Transferase; supply MgATP while keeping zinc absent (Why this does not fit)
This assigns a phosphate-transfer label without following the water-mediated cleavage and substitutes ATP for the experimentally depleted component. The matched zinc-retaining control remains active, while selective zinc loss tracks activity loss. Hydrolysis with a zinc add-back test is best supported.
What products identify the measured cleavage?
Alcohol plus water-derived free phosphate identify hydrolytic cleavage.
Which processing control preserves activity?
The identically processed zinc-retaining sample preserves activity.
Which variable should the reconstitution test restore?
The reconstitution test should restore zinc.
D. Hydrolase; restore zinc at matched free-metal conditions (Best answer)
The labeled-water and product data identify hydrolysis. Selective zinc loss tracks activity loss despite preserved folding, adequate other cofactors and controls against residual reagent or processing damage. Zinc add-back is therefore the most discriminating first reconstitution test. Recovery is a prediction to test, not an outcome already established; MgATP is not a generic replacement for a missing metal.
What class follows from the water-mediated reaction?
The measured reaction is hydrolysis.
What does the zinc-retaining processing control argue against?
The control argues against processing alone causing the activity loss.
What does the residual-reagent control argue against?
The control argues against the measured residual reagent causing the activity loss.
Which reconstitution tests the remaining component-specific explanation?
Zinc add-back tests the component-specific explanation.
Takeaway: Reaction chemistry defines class; controlled component loss selects the reconstitution test.
A. NADH entry through complex I; succinate-supported respiration decreases (Best answer)
Failure of leak rescue with low potential opposes simple proton-return restriction. Succinate rescue with intact NADH generation localizes the defect to the NADH-entry route through I rather than the shared downstream route. Succinate still requires III, so a new III block decreases its respiration.
What does failure of leak rescue argue against?
Failure of leak rescue argues against proton-return resistance as the sole defect.
What localization follows from succinate rescue with intact NADH generation?
The defect localizes to NADH entry through complex I.
Does the rescued succinate route still require complex III?
The succinate route still requires complex III.
What follows when III is then blocked?
Succinate-supported respiration decreases.
B. NADH entry through complex I; succinate-supported respiration remains near 90% (Why this does not fit)
The initial localization fits. The prediction mistakes an entry bypass for bypass of the downstream route. Succinate enters at II but still passes through III to oxygen, so inhibiting III defeats the rescue.
Where do succinate-derived electrons enter?
Succinate-derived electrons enter through complex II.
Which newly inhibited component remains downstream?
Complex III remains downstream of complex II.
C. ATP-synthase proton return; succinate-supported respiration decreases (Why this does not fit)
A new III block would indeed stop the succinate route. The proposed initial lesion conflicts with low potential and failure of calibrated leak to restore oxygen use. Simple synthase-pathway restriction instead tends to retain a high gradient that leak can relieve.
What gradient tendency is expected from simple proton-return restriction?
Simple proton-return restriction tends to raise membrane potential.
What supplied perturbation further opposes that target?
Calibrated leak fails to restore oxygen use.
D. Shared transfer through complex III or IV; succinate-supported respiration decreases (Why this does not fit)
A III block would reduce respiration, but the initial shared-route localization is contradicted by succinate restoring both oxygen use and potential. Succinate must use the shared downstream route, so that rescue localizes X upstream of it.
What observation tests whether the shared downstream route remains functional?
Succinate restores oxygen use and membrane potential.
Why does that oppose a shared III/IV block by X?
Succinate-derived electrons still require complexes III and IV.
Takeaway: An entry bypass supports downstream electron flow only while the downstream route remains functional.
A. A restricts terminal electron transfer; B increases proton leak (Why this does not fit)
B fits low potential with increased oxygen use. A does not fit a terminal block because leak restores near-normal oxygen use, requiring the electron-transfer route to remain functional. Its high potential instead supports restricted proton return.
What does leak-restored oxygen use establish for A?
The electron-transfer route can still support near-normal oxygen use after A.
Why does that oppose a terminal electron-transfer block?
A proton leak cannot bypass blocked electron delivery to oxygen.
B. A restricts ATP-synthase proton return; B restricts terminal electron transfer (Why this does not fit)
A fits high potential and leak-rescuable respiratory slowing. B instead has increased oxygen use with low potential, inconsistent with terminal transfer being its limiting block under these supplied conditions.
Which B measurement opposes a limiting terminal transfer block?
B raises oxygen use to 150% of control.
What mechanism fits that response together with low potential?
Increased proton leak fits the combined response.
C. A restricts ATP-synthase proton return; B increases proton leak (Best answer)
A’s high potential suggests proton-return resistance; leak restores respiration without ATP, showing an intact respiratory route but restricted synthase-pathway use. B dissipates potential while increasing oxygen use, consistent with proton leak. ATP reduction alone would not separate these mechanisms.
What does high potential during A-associated respiratory slowing suggest?
High potential suggests resistance to proton return.
What does respiratory rescue without ATP rescue support for A?
The rescue supports ATP-synthase-pathway restriction with an intact respiratory route.
What does low potential with increased oxygen use support for B?
The combined B response supports increased proton leak.
D. A restricts terminal electron transfer; B restricts ATP-synthase proton return (Why this does not fit)
A’s oxygen use recovers after leak, opposing terminal blockade. B’s low potential with high oxygen use opposes simple synthase-pathway restriction, which tends to retain potential and slow respiration. The assignments are both inconsistent with the joint measurements.
Which A result rejects terminal transfer restriction?
A’s oxygen use returns to 95% after calibrated leak.
Which B pattern rejects simple proton-return restriction?
B lowers potential while increasing oxygen use.
Takeaway: Localize mitochondrial perturbations using potential, oxygen use and ATP together.
A. Oxidative production 3; subsequent net change -1 micromol/L/min (Why this does not fit)
Oxidative production 3 follows after correcting lactate labeling and subtracting glycolytic supply from total ATP production. Keeping net change -1 ignores the predicted loss of half the glycolytic supply, from 6 to 3. New net ATP change is 3+3-10 = -4.
What glycolytic ATP supply follows from corrected lactate appearance?
Glycolytic ATP supply is 3/0.5 = 6 micromol/L/min.
What glycolytic supply remains after the perturbation?
Glycolytic supply becomes 3 micromol/L/min.
What new ATP balance follows?
The new ATP balance is 3+3-10 = -4 micromol/L/min.
B. Oxidative production 3; subsequent net change -4 micromol/L/min (Best answer)
ATP loss of 1 against consumption 10 implies total production 9. Correcting labeled lactate for 50% precursor enrichment gives glycolytic supply 6, leaving oxidative production 3. Halving glycolysis leaves 3+3 production against consumption 10, so net change becomes -4. Oxygen use alone does not supply either ATP-production term.
What total ATP production follows from measured loss and consumption?
Total production is 10-1 = 9 micromol/L/min.
What glycolytic ATP supply follows from the tracer correction?
Glycolytic supply is 3/0.5 = 6 micromol/L/min.
What residual oxidative production follows?
Oxidative production is 9-6 = 3 micromol/L/min.
What supply remains after halving glycolysis?
Total supply becomes 3 oxidative plus 3 glycolytic = 6 micromol/L/min.
What net ATP change follows?
The net ATP change is 6-10 = -4 micromol/L/min.
C. Oxidative production 6; subsequent net change -2.5 micromol/L/min (Why this does not fit)
These values treat labeled lactate 3 as total lactate despite 50% precursor enrichment. That error assigns glycolysis 3 and oxidative production 9-3 = 6, then gives 6+1.5-10 = -2.5. Correcting enrichment doubles glycolytic supply to 6, leaving oxidative supply 3 and subsequent net change -4.
What omitted correction produces glycolytic supply 3?
The calculation omits division by precursor enrichment 0.5.
What oxidative supply follows after that correction?
Corrected oxidative supply is 9-6 = 3 micromol/L/min.
What subsequent net change follows?
The corrected subsequent net change is -4 micromol/L/min.
D. Oxidative production 6; subsequent net change -1 micromol/L/min (Why this does not fit)
This both uses labeled lactate as total lactate and retains the pre-perturbation balance despite reduced glycolysis. Enrichment correction gives glycolytic production 6, so residual oxidative production is 3. Losing half the glycolytic term decreases net ATP change from -1 to -4. Any reverse synthase consumption is already included in demand and must not be counted again.
What corrected glycolytic supply follows from the labeled rate?
Corrected glycolytic supply is 6 micromol/L/min.
What supply is lost when that flux halves?
The lost supply is 3 micromol/L/min.
What new net change follows from losing that supply?
The new net change is -1-3 = -4 micromol/L/min.
Where is reverse ATP-synthase hydrolysis already included?
Reverse ATP-synthase hydrolysis is included in total consumption 10.
Takeaway: Infer the ATP-source split before predicting a selective loss of compensation.
A. Give the pulse reading priority over COHb when estimating oxygen carriage; evaluate cyanide from the exposure (Why this does not fit)
The exposure warrants cyanide assessment, but conventional pulse oximetry is unreliable with carboxyhemoglobin. The measured COHb cannot be discounted because SpO2 looks normal; oxygen-carriage impairment matters when considering a methemoglobin-forming drug.
Which oxygen-delivery abnormality does COHb identify?
COHb identifies impaired oxygen carriage by the hemoglobin pool.
Can conventional SpO2 exclude that impairment?
Conventional SpO2 cannot reliably exclude impairment from carboxyhemoglobin.
B. Assess concurrent cyanide toxicity; treat nitrite as improving utilization without affecting oxygen carriage (Why this does not fit)
Concurrent cyanide assessment is appropriate. Treating nitrite as neutral for oxygen carriage misses its methemoglobin-forming action, which matters when COHb already impairs carriage. CO can also impair cellular oxygen use, so delivery and utilization are not toxin-exclusive categories.
What part of the proposed mixed-exposure assessment is appropriate?
Concurrent cyanide toxicity remains possible despite measured CO exposure.
What nitrite effect contradicts oxygen-carriage neutrality?
Nitrite produces methemoglobin that can further impair oxygen carriage.
Does CO affect only oxygen delivery?
CO can also impair cellular oxygen utilization.
C. Use lactate magnitude to favor nitrite; use COHb only to guide oxygen duration (Why this does not fit)
High lactate can support severe metabolic stress but does not alone choose the antidote. COHb affects the risk of further impairing oxygen carriage with nitrite, not merely the duration of oxygen therapy. Concurrent clinical assessment must integrate both exposures.
Can lactate alone select a cyanide antidote?
Lactate alone cannot select a cyanide antidote.
What antidote-related issue does COHb raise?
COHb raises concern about additional oxygen-carriage loss from methemoglobin formation.
D. Assess mixed delivery and utilization injury; account for nitrite’s added oxygen-carriage cost (Best answer)
Measured COHb establishes an oxygen-carriage problem despite reassuring conventional SpO2. Lactate does not uniquely identify the toxin, so possible cyanide-related utilization injury must also be assessed. Nitrite produces methemoglobin and can worsen carriage in smoke exposure. This assessment proceeds alongside urgent treatment, without waiting for confirmatory testing when cyanide is strongly suspected. CO can also impair cellular utilization; these mechanisms are not exclusive toxin labels.
What does measured COHb add despite normal conventional SpO2?
